Aussie biotech aims high in race to cure cancer
Every year 45,000 of the most respected professionals in oncology gather at the American Society...
Every year 45,000 of the most respected professionals in oncology gather at the American Society...
Last month, the best and brightest minds in oncology gathered (virtually) for the American Society...
Two of Prescient Therapeutics' (PTX) assets have been handpicked for a COVID-19 antiviral testing program....
Prescient Therapeutics Limited (ASX:PTX) has signed a research agreement with the Peter Doherty Institute for Infection and...
Clinical stage oncology company Prescient Therapeutics (ASX: PTX) has revealed two of its assets have been selected...
PTX has acquired the exclusive global licence to a universal immune receptor (UIR) platform from...
Prescient Therapeutics (ASX: PTX) CEO and Managing Director Steven Yatomi-Clarke joined Steve Darling from Proactive...
Capital dedicated by local investors to risky investments that was once largely tied up in...
The company’s goal is to harness OmniCAR’s innate adaptability and control to develop novel cell...
Anti-cancer biotech company Prescient Therapeutics (PTX) has received two key licences to build a new...
This investor centre was built by Reach Markets
©2022 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.